Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting-Reference-Cited by-同舟云学术

Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting

Published:2022-11-24 Issue:2 Volume:16 Page:305-312
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Muntañola Ana¹,Arguiñano‐Pérez José María²,Dávila Julio³,de Villambrosia Sonia González⁴,Carpio Cecilia⁵⁶,Jiménez‐Ubieto Ana⁷,Salar Antonio⁸⁹¹⁰^ORCID,

Affiliation:

1. Department of Hematology Hospital Universitari Mutua Terrassa Terrassa Spain

2. Department of Hematology Hospital Universitario de Navarra Pamplona Spain

3. Department of Hematology Complejo Asistencial de Ávila Ávila Spain

4. Department of Hematology Hospital Universitario Marqués de Valdecilla/IDIVAL Santander Spain

5. Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital Barcelona Spain

6. Department of Medicine Universitat Autònoma de Barcelona Barcelona Spain

7. Department of Hematology Hospital 12 de Octubre Madrid Spain

8. Department of Hematology Hospital del Mar Barcelona Spain

9. Group of Applied Clinical Research in Hematology Cancer Research Program‐IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain

10. Pompeu Fabra University Barcelona Spain

Funder

Sandoz

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13450

Reference37 articles.

1. Tolerability and safety of rituximab (MabThera®)

2. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

3. Review of the Safety and Feasibility of Rapid Infusion of Rituximab

4. Summary of product characteristics: MabThera. Accessed 22 November 2022. Available from:https://www.ema.europa.eu/en/documents/product‐information/mabthera‐epar‐product‐information_en.pdf

5. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries;Cock E;PLoS One,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2023-12-02